Stevanato Group（STVN N）株式概要ステヴァナート・グループS.p.A.は、ヨーロッパ、中東、アフリカ、北米、南米、アジア太平洋地域において、バイオ医薬品およびヘルスケア産業向けの統合ソリューションを提供するための製品およびプロセスの設計、製造、販売を行っている。 詳細STVN N ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長3/6過去の実績5/6財務の健全性6/6配当金0/6報酬株価収益率（ 30.3 x）は、 Life Sciences業界平均（ 37.6 x）を下回っています。収益は年間16.14%増加すると予測されています 過去1年間で収益は12.6%増加しました リスク分析株式の流動性は非常に低い 過去3か月間に大規模なインサイダー売却が発生 すべてのリスクチェックを見るSTVN N Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW477,573 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA477,573 investors already sharing narrativesYour Fair ValueMex$Current PriceMex$246.0011.5% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture02b2016201920222025202620282031Revenue €1.8bEarnings €208.3mAdvancedSet Fair ValueView all narrativesStevanato Group S.p.A. 競合他社Sotera HealthSymbol: NasdaqGS:SHCMarket cap: US$5.1bAnthem BiosciencesSymbol: NSEI:ANTHEMMarket cap: ₹455.7bGenomma Lab Internacional. deSymbol: BMV:LAB BMarket cap: Mex$14.3bSiegfried HoldingSymbol: SWX:SFZNMarket cap: CHF 3.3b価格と性能株価の高値、安値、推移の概要Stevanato Group過去の株価現在の株価US$246.0052週高値US$266.1252週安値US$246.00ベータ0.781ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化-50.40%5年間の変化n/aIPOからの変化-34.29%最新ニュースお知らせ • Jul 31Stevanato Group Announces Marketing Authorizations for Liraglutide-Based Combination Products Incorporating Alina Pen Injector in Multiple European CountriesStevanato Group S.p. A announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders. The approved configurations include Alina 30, developed for liraglutide-based therapies for diabetes, and Alina 50, designed for liraglutide-based weight management applications. Both variants are part of Stevanato Group's broader Alina variable-dose pen injector platform, which offers multiple pre-configured variants for GLP-1s and other injectable therapies. Alina features a dial-a-dose mechanism with visual, audible, and tactile feedback during dose selection and injection, and compatibility with ISO standard 3 mL glass cartridges. The platform has been designed to support manufacturing scalability, and integration into existing pharmaceutical fill and finish and final assembly supply chains. These authorizations come at a time when injectable therapies are playing an increasingly important role in healthcare, driven by the ongoing expansion of GLP-1 treatments and the broader shift towards patient-centric models of care and self-administration. Through its proprietary device portfolio – including Alina (variable-dose, pen injector), Deora (fixed-dose, pen injector), Aidaptus (autoinjector) and Vertiva (on-body delivery system) – Stevanato Group is expanding its drug delivery capabilities to support pharmaceutical and biotechnology companies developing next-generation therapies. Alina is manufactured within Stevanato Group's Drug Delivery Systems operations and leverages the Company's integrated expertise across pharmaceutical glass containers, engineering technologies, analytical services and device manufacturing. The platform has been designed to offer pharmaceutical partners a flexible and production-ready solution capable of supporting commercial-scale deployment. Alina is a variable-dose, disposable pen injector platform designed for subcutaneous drug delivery. The platform can accommodate doses from 0.01 mL up to 0.75 mL and includes multiple pre-configured variants developed for GLP-1 and other injectable therapies. Alina combines familiar handling, enhanced dose readability and flexible customization options to support a wide range of therapeutic requirements.お知らせ • Jul 21Stevanato Group S.p.A. to Report Q2, 2026 Results on Aug 04, 2026Stevanato Group S.p.A. announced that they will report Q2, 2026 results at 6:30 AM, US Eastern Standard Time on Aug 04, 2026お知らせ • Jun 10Stevanato Group Introduces Deora Pen Injector Platform for Subcutaneous Delivery in Diabetes and Weight ManagementStevanato Group S.p.A. introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is Stevanato Group’s multi-use, fixed-dose pen injector designed for subcutaneous drug delivery in therapies such as diabetes and weight management. Featuring an intuitive pull-push mechanism, the device simplifies dose administration by eliminating the need for manual dose selection: users pull to set the dose and push to inject, supporting consistent delivery across multiple administrations. The platform accommodates fixed-dose volumes up to 0.75 mL and is compatible with standard 1.5 mL and 3 mL cartridges, offering flexibility across a range of therapeutic applications. Engineered with patient usability in mind, Deora™ provides tactile, visual, and audible feedback during operation, helping reduce common sources of use error. Its architecture is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing for pharmaceutical partners. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL. The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing. Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format. Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs. Deora™ leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialization. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners. Together, these characteristics position Deora™ as a platform intended to support partners as they advance early development programs and prepare for future scale-up.お知らせ • Jun 04Stevanato Group S.p.A. Approves Dividend on Class A ShareStevanato Group S.p.A. at its Ordinary and Extraordinary Meeting of Shareholders held on May 26, 2026 approved distribution of dividends in the amount of EUR 0.054 for each outstanding Class A and ordinary share of the Company, net of the treasury shares.お知らせ • May 30Stevanato Group S.p.A. Appoints Peter Soelkner as Non-Executive Director, Effective 26 May 2026Oxford Biomedica plc announced that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independent Non-Executive Director has been appointed as a Non-Executive Director of Stevanato Group S.p.A, a NASDAQ listed company with effect from 26 May 2026.お知らせ • May 12Stevanato Group S.p.A., Annual General Meeting, May 26, 2026Stevanato Group S.p.A., Annual General Meeting, May 26, 2026.最新情報をもっと見るRecent updatesお知らせ • Jul 31Stevanato Group Announces Marketing Authorizations for Liraglutide-Based Combination Products Incorporating Alina Pen Injector in Multiple European CountriesStevanato Group S.p. A announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders. The approved configurations include Alina 30, developed for liraglutide-based therapies for diabetes, and Alina 50, designed for liraglutide-based weight management applications. Both variants are part of Stevanato Group's broader Alina variable-dose pen injector platform, which offers multiple pre-configured variants for GLP-1s and other injectable therapies. Alina features a dial-a-dose mechanism with visual, audible, and tactile feedback during dose selection and injection, and compatibility with ISO standard 3 mL glass cartridges. The platform has been designed to support manufacturing scalability, and integration into existing pharmaceutical fill and finish and final assembly supply chains. These authorizations come at a time when injectable therapies are playing an increasingly important role in healthcare, driven by the ongoing expansion of GLP-1 treatments and the broader shift towards patient-centric models of care and self-administration. Through its proprietary device portfolio – including Alina (variable-dose, pen injector), Deora (fixed-dose, pen injector), Aidaptus (autoinjector) and Vertiva (on-body delivery system) – Stevanato Group is expanding its drug delivery capabilities to support pharmaceutical and biotechnology companies developing next-generation therapies. Alina is manufactured within Stevanato Group's Drug Delivery Systems operations and leverages the Company's integrated expertise across pharmaceutical glass containers, engineering technologies, analytical services and device manufacturing. The platform has been designed to offer pharmaceutical partners a flexible and production-ready solution capable of supporting commercial-scale deployment. Alina is a variable-dose, disposable pen injector platform designed for subcutaneous drug delivery. The platform can accommodate doses from 0.01 mL up to 0.75 mL and includes multiple pre-configured variants developed for GLP-1 and other injectable therapies. Alina combines familiar handling, enhanced dose readability and flexible customization options to support a wide range of therapeutic requirements.お知らせ • Jul 21Stevanato Group S.p.A. to Report Q2, 2026 Results on Aug 04, 2026Stevanato Group S.p.A. announced that they will report Q2, 2026 results at 6:30 AM, US Eastern Standard Time on Aug 04, 2026お知らせ • Jun 10Stevanato Group Introduces Deora Pen Injector Platform for Subcutaneous Delivery in Diabetes and Weight ManagementStevanato Group S.p.A. introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is Stevanato Group’s multi-use, fixed-dose pen injector designed for subcutaneous drug delivery in therapies such as diabetes and weight management. Featuring an intuitive pull-push mechanism, the device simplifies dose administration by eliminating the need for manual dose selection: users pull to set the dose and push to inject, supporting consistent delivery across multiple administrations. The platform accommodates fixed-dose volumes up to 0.75 mL and is compatible with standard 1.5 mL and 3 mL cartridges, offering flexibility across a range of therapeutic applications. Engineered with patient usability in mind, Deora™ provides tactile, visual, and audible feedback during operation, helping reduce common sources of use error. Its architecture is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing for pharmaceutical partners. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL. The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing. Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format. Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs. Deora™ leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialization. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners. Together, these characteristics position Deora™ as a platform intended to support partners as they advance early development programs and prepare for future scale-up.お知らせ • Jun 04Stevanato Group S.p.A. Approves Dividend on Class A ShareStevanato Group S.p.A. at its Ordinary and Extraordinary Meeting of Shareholders held on May 26, 2026 approved distribution of dividends in the amount of EUR 0.054 for each outstanding Class A and ordinary share of the Company, net of the treasury shares.お知らせ • May 30Stevanato Group S.p.A. Appoints Peter Soelkner as Non-Executive Director, Effective 26 May 2026Oxford Biomedica plc announced that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independent Non-Executive Director has been appointed as a Non-Executive Director of Stevanato Group S.p.A, a NASDAQ listed company with effect from 26 May 2026.お知らせ • May 12Stevanato Group S.p.A., Annual General Meeting, May 26, 2026Stevanato Group S.p.A., Annual General Meeting, May 26, 2026.お知らせ • May 09Stevanato Group S.p.A. Maintains Earnings Guidance for the Fiscal Year 2026Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be in the range of EUR 1,260.0 million to EAR 1,290.0 million. Operating profit to be EUR 212.7 million to EUR 227.8 million. Net profit to be EUR 149.6 million to EUR 160.7 million. Diluted EPS to be EUR 0.55 to EUR 0.59.お知らせ • Apr 24Stevanato Group S.p.A. to Report Q1, 2026 Results on May 07, 2026Stevanato Group S.p.A. announced that they will report Q1, 2026 results at 6:30 AM, Eastern Daylight on May 07, 2026お知らせ • Mar 05Stevanato Group S.P.A. Provides Earnings Guidance for the Fiscal 2026Stevanato Group S.p.A. provided earnings guidance for the fiscal 2026. For the year, the company expected revenue in the range of €1.26 billion to €1.29 billion; Operating Profit of €212.7 million to €227.8 million; Net Profit of €149.6 million to €160.7 million; Diluted EPS of €0.55 to €0.59.お知らせ • Feb 19Stevanato Group S.p.A. to Report Q4, 2025 Results on Mar 04, 2026Stevanato Group S.p.A. announced that they will report Q4, 2025 results at 6:30 AM, US Eastern Standard Time on Mar 04, 2026お知らせ • Nov 07Stevanato Group S.P.A. Maintains Revenue Guidance for the 2025Stevanato Group S.p.A. maintained revenue guidance for the 2025. For the period, the company expects Revenue in the range of €1.160 billion to €1.190 billion.お知らせ • Oct 22Stevanato Group S.p.A. to Report Q3, 2025 Results on Nov 06, 2025Stevanato Group S.p.A. announced that they will report Q3, 2025 results at 6:30 AM, Eastern Standard Time on Nov 06, 2025お知らせ • Aug 05Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the period, the company continues to expect revenue in the range of €1.160 billion to €1.190 billion.お知らせ • Jul 23Stevanato Group S.p.A. to Report Q2, 2025 Results on Aug 05, 2025Stevanato Group S.p.A. announced that they will report Q2, 2025 results at 6:30 AM, US Eastern Standard Time on Aug 05, 2025お知らせ • Jun 10+ 1 more updateStevanato Group S.p.A. Approves Board AppointmentsStevanato Group S.p.A. at its Ordinary Meeting of Shareholders held on May 23, 2025 approved appointment of Sue Jean Lin and Elisabetta Magistretti to its board of directors.お知らせ • May 08Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the year, the company expects revenue in the range of €1.160 billion to €1.190 billion.お知らせ • May 05Stevanato Group S.p.A., Annual General Meeting, May 23, 2025Stevanato Group S.p.A., Annual General Meeting, May 23, 2025, at 16:00 W. Europe Standard Time.お知らせ • Apr 25Stevanato Group S.p.A. to Report Q1, 2025 Results on May 08, 2025Stevanato Group S.p.A. announced that they will report Q1, 2025 results at 6:30 AM, Eastern Standard Time on May 08, 2025お知らせ • Mar 06Stevanato Group S.p.A. Provides Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. provided earnings guidance for the fiscal year 2025. For the year, the Company expected revenue in the range of €1,160 million to €1,190 million.お知らせ • Feb 25Stevanato Group S.p.A. to Report Q4, 2024 Results on Mar 06, 2025Stevanato Group S.p.A. announced that they will report Q4, 2024 results at 6:30 AM, US Eastern Standard Time on Mar 06, 2025お知らせ • Nov 05Stevanato Group S.P.A. Provides Earnings Guidance for the Full Year 2024Stevanato Group S.p.A. provided earnings guidance for the full year 2024. for the year, the company expects reported revenue of €1,090.0 million to €1,110.0 million, reported Operating Profit of €155.8 million to €161.8 million, reported Net Profit of €115.0 million to €119.4 million, reported Diluted EPS €0.42-€0.44.お知らせ • Oct 23Stevanato Group S.p.A. to Report Q3, 2024 Results on Nov 05, 2024Stevanato Group S.p.A. announced that they will report Q3, 2024 results at 6:30 AM, US Eastern Standard Time on Nov 05, 2024お知らせ • Oct 01Stevanato Group S.p.A. to Introduce Its Large-Volume Vertiva 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI MilanStevanato Group S.p. A. announced the expansion of its Vertiva platform, which will include a 10mL option to be presented at CPHI Milan in October. The Vertiva®? easy-to-use platform can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-content bolus injections. This flexibility makes the platform ideal for administering a wide range of small molecule and biologic therapies, enabling treatment for conditions such as cardiovascular and metabolic disorders, oncology, immunology, and pain management. The Vertiva®? platform features a unique design with a single-use pod containing a pre-filled, pre-loaded cartridge, paired with a reusable, smart controller that communicates with a patented and magnetically coupled drive mechanism. The pod, securely interlocked with the controller, contains a pre-filled glass cartridge available in formats ranging from 3mL up to 10mL and is assembled at the factory for immediate use. This simplifies home-based treatment initiation, offering patients a safe and comfortable experience. A recent wearability study underscored this sentiment and revealed that Vertiva®? 10mL is generally well-accepted by patients who found it comfortable to wear. The device proved to securely adhere to the body without restricting movement, allowing patients to go about their daily activities easily. The smart controller provides the option to record patient usage data, which can be transferred via Bluetooth to digital health applications. Additionally, the two-part system allows for easy separation of the reusable controller from the disposable pod after treatment, significantly reducing the environmental impact of electronic components and enhancing the device's overall sustainability. Stevanato Group will leverage its integrated capabilities and its existing partnership with Thermo Fisher Scientific to bring Vertiva®? 10mL to market. Along with the proprietary device platform, Stevanato Group will offer its pre-sterilized EZ-fill®? cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services. The unparalleled combination of capabilities from two established industry providers will support pharma companies from drug development through to the final packaged product, reducing risks and accelerating time-to-market. Demonstrations of Vertiva®? 10mL will be available at CPHI in Milan (Oct 8-10) at Stevanato Group's booth, 20C1.お知らせ • Aug 06Stevanato Group S.p.A. Updates Earnings Guidance for the Year 2024Stevanato Group S.p.A. updated earnings guidance for the year 2024. For the year, the company expects reported revenue to be between €1,090 million to €1,110 million. Reported operating profit to be between €162.9 million to €170.9 million. Reported net profit to be between €119.5 million to €125.5 million. Reported diluted EPS to be between €0.44 to €0.46.お知らせ • Jul 25Stevanato Group S.p.A. to Report Q2, 2024 Results on Aug 06, 2024Stevanato Group S.p.A. announced that they will report Q2, 2024 results at 6:30 AM, US Eastern Standard Time on Aug 06, 2024お知らせ • May 29Stevanato Group S.P.A. Announces Chief Executive Officer ChangesStevanato Group S.P.A. announced that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024. Mr. Moro will remain on the Company’s Board of Directors. Mr. Stevanato has held the position of Executive Chairman since 2021 and he previously served as Chief Executive Officer of Stevanato Group from 1998 to 2021. He is the driving force behind the Group’s long-term strategic vision and integrated value proposition. Mr. Stevanato is responsible for leading the Company’s global expansion over the last two decades, expanding the Company’s diversified product portfolio, establishing the Group’s science-based technology excellence centers, enhancing its research and development capabilities, and leading the Company through its initial public offering.お知らせ • May 10Stevanato Group S.P.A. Provides Revenue Guidance for 2024Stevanato Group S.p.A. provided revenue guidance for 2024. For the period, the company expects revenue in the range of €1,125 million to €1,155 million.お知らせ • Apr 28Stevanato Group S.p.A. to Report Q1, 2024 Results on May 09, 2024Stevanato Group S.p.A. announced that they will report Q1, 2024 results at 6:30 AM, US Eastern Standard Time on May 09, 2024お知らせ • Apr 05Stevanato Group S.p.A. Announces the Appointment of Ugo Gay as Chief Operations OfficerStevanato Group S.p.A. announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). The addition of Ugo Gay underscores Stevanato Group’s unwavering commitment to driving operational efficiency, process standardization, and sustainable growth across its global value chain. Ugo Gay brings to Stevanato Group nearly three decades of experience in industry, business management, supply chain, and operations. Prior to joining Stevanato Group, Ugo held key leadership positions at renowned organizations, including the Biological Chemotherapy Institute of Turin and Diasorin, an Italian multinational biotechnology company. At Diasorin, Ugo served in various roles, from Sales to Industrial Operations, culminating in his tenure as CEO and General Manager of the new subsidiary Diasorin Italia S.p.A. In his new role as COO of Stevanato Group, Ugo Gay will shape and execute sourcing, planning, and manufacturing strategies to help drive the Company's growth and achieve its business goals and vision. With a keen focus on maximizing returns on investments and driving efficiencies, Ugo will oversee priority strategic projects and lead the development and management of information systems to support the Company's development and standardization of processes. Ugo Gay officially assumed his role as Chief Operations Officer on March 25, 2024, and will be based at Piombino Dese.お知らせ • Mar 22Stevanato Group S.p.A. has filed a Follow-on Equity Offering in the amount of $300 million.Stevanato Group S.p.A. has filed a Follow-on Equity Offering in the amount of $300 million. Security Name: Common Stock Security Type: Common Stockお知らせ • Mar 07Stevanato Group S.P.A. Provides Revenue Guidance for the Full Year of 2024Stevanato Group S.p.A. provided revenue guidance for the full year of 2024. For the year, company expects Revenue in the range of €1,180 million to €1,210 million.お知らせ • Feb 23Stevanato Group S.p.A. to Report Q4, 2023 Results on Mar 07, 2024Stevanato Group S.p.A. announced that they will report Q4, 2023 results at 6:30 AM, Eastern Standard Time on Mar 07, 2024お知らせ • Jan 24Stevanato Group S.p.A. Launches EZ-fill®? Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and CommercializationStevanato Group S.p. A. unveiled two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers (TEC). In a context where reducing time-to-market is key, Stevanato Group's new EZ-fill®? Kit offers fast access to a customizable and versatile solution to pharma and biotech companies needing to efficiently fill small batches with high-quality injectable formulations during clinical trials or commercial phases. The surge the industry has seen in biopharmaceuticals treating various diseases in several therapeutical areas may signal a significant growth potential for pharmaceutical companies. Injectables, comprising more than 60% of the over 21,000 drugs currently in development, of which 44% are biopharmaceuticals, require high-performance primary packaging and delivery technologies for proper storage and administration. The company’s EZ-fill® Kit builds on its existing ready-to-use platform of pre-sterilized containment solutions – vials, cartridges, and syringes – allowing customers to effectively screen different primary packaging in combination with drug products. The kit will be available as a modular box made up of glass ready-to-use drug containers and add-on components on request, shipped by courier. As a result, the platform can bring enhanced levels of quality and safety to patients across the entire drug life cycle and improve the rate at which new drugs enter the market. EZ-fill® Kit will be presented at Pharmapack and is expected to be available commercially beginning in the second quarter of 2024.お知らせ • Nov 01Stevanato Group S.P.A. Reiterates Revenue Guidance for the Full Year 2023Stevanato Group S.p.A. reiterated revenue guidance for the full year 2023. For the year, company expects Revenue in the range of €1.085 billion to €1.115 billion.お知らせ • Oct 18Stevanato Group S.p.A. to Report Q3, 2023 Results on Oct 31, 2023Stevanato Group S.p.A. announced that they will report Q3, 2023 results at 6:30 AM, US Eastern Standard Time on Oct 31, 2023Reported Earnings • Aug 08Second quarter 2023 earnings released: EPS: €0.13 (vs €0.12 in 2Q 2022)Second quarter 2023 results: EPS: €0.13 (up from €0.12 in 2Q 2022). Revenue: €255.3m (up 9.0% from 2Q 2022). Net income: €34.2m (up 12% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Global Life Sciences industry.お知らせ • Jul 29Stevanato Group S.P.A. Provides Revenue Guidance for the Year 2023Stevanato Group S.p.A. provided revenue guidance for the year 2023. For the period, the company expects revenue in the range of €1.085 billion to €1.115 billion.お知らせ • Jul 15Stevanato Group S.p.A. to Report Q2, 2023 Results on Jul 28, 2023Stevanato Group S.p.A. announced that they will report Q2, 2023 results at 6:30 AM, US Eastern Standard Time on Jul 28, 2023お知らせ • Jun 13Stevanato Group S.p.A. Unveils Vertiva On-Body Delivery System Platform for Wide Range of Injectable Therapies and for Large Delivery Volumes (Up to 10mL)Stevanato Group S.p.A. unveiled Vertiva, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies. Vertiva's unique design consists of a single-use pod with a pre-filled and pre-loaded 3mL ISO cartridge, and a multi-use controller, offering potential sustainability and affordability benefits. These two parts communicate through a patented magnetically coupled drive mechanism. The device can adapt to different delivery profiles and can enable the administration of small-molecule drugs and biologics. Vertiva's design is under development also to cover a broad range of volumes up to 10mL. In the Vertiva device the cartridge is preloaded and sealed into the pod during factory assembly allowing the patient to benefit from simplified treatment initiation. Administrations can be conducted more comfortably at home, and the connectivity options of Vertiva can be ready for digital health applications. Upon treatment, the pod and controller can be more easily separated, and the controller can be reused, thereby reducing the environmental impact of electronic components. Fully programmable to deliver micro-precision basal doses and full-content bolus injections, Vertiva is intended to be suitable for awide range of therapies, such as cardiovascular and metabolic disorders, oncology, immunology, and pain diseases. Vertiva platform can also accommodate different customizations, including primary packaging format for larger injection volumes, delivery duration, and user interface. The Vertiva brand name takes its cue from the word 'versatility' and suggests that the delivery profile is flexible, as it is programmable for basal and bolus delivery. The name also evokes ease of use for patients. Stevanato Group will leverage the recently announced collaboration with Thermo Fisher Scientific to bring Vertiva to market. The platform will be offered as an integrated device and fill-and-finish solution to streamline the management of the pharmaceutical supply chain. The unparalleled combination of capabilities from two established industry providers can support pharma companies from drug development through to the final packaged product. Along with the proprietary device platform, Stevanato Group will offer its pre-sterilized EZ-fill cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services.お知らせ • Jun 08Stevanato Group S.p.A. Announces Dividend, Payable on July 17, 2023Stevanato Group S.p.A. announced that it has changed the previously announced ex-dividend date of June 5, 2023 for its cash dividend of EUR 0.054 per share, payable on July 17, 2023, to comply with New York Stock Exchange rules. The new ex-dividend date for the dividend will be June 7, 2023, and the record date remains June 6, 2023. The dividend will continue to be payable on July 17, 2023.お知らせ • May 05Stevanato Group S.p.A. Reiterates Earnings Guidance for the Year 2023Stevanato Group S.p.A. reiterated earnings guidance for the year 2023. The Company is reiterating its fiscal year 2023 guidance and still expects: Revenue in the range of €1.085 billion to €1.115 billion, Operating Profit in the range of €199.9 million to €211.9 million, net profit in the range of €147.8 million to €156.9 million and Diluted EPS in the range of €0.56 to €0.59.Reported Earnings • Mar 04Full year 2022 earnings released: EPS: €0.54 (vs €0.53 in FY 2021)Full year 2022 results: EPS: €0.54 (up from €0.53 in FY 2021). Revenue: €983.7m (up 17% from FY 2021). Net income: €143.0m (up 6.5% from FY 2021). Profit margin: 14% (down from 16% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Global Life Sciences industry.お知らせ • Feb 17Stevanato Group S.p.A. to Report Q4, 2022 Results on Mar 02, 2023Stevanato Group S.p.A. announced that they will report Q4, 2022 results at 6:30 AM, US Eastern Standard Time on Mar 02, 2023Valuation Update With 7 Day Price Move • Dec 09Investor sentiment improved over the past weekAfter last week's 15% share price gain to Mex$332, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 31x in the Life Sciences industry globally. Simply Wall St's valuation model estimates the intrinsic value at Mex$221 per share.株主還元STVN NMX Life SciencesMX 市場7D0%0%0%1Yn/a0%0%株主還元を見る業界別リターン: STVN NがMX Life Sciences業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: STVN N MX市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is STVN N's price volatile compared to industry and market?STVN N volatilitySTVN N Average Weekly Movementn/aLife Sciences Industry Average Movement0%Market Average Movement0%10% most volatile stocks in MX Market0%10% least volatile stocks in MX Market0%安定した株価: STVN Nの株価は、 MX市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のSTVN Nのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19496,010Franco Stevanatowww.stevanatogroup.comステヴァナート・グループS p.A.は、ヨーロッパ、中東、アフリカ、北米、南米、アジア太平洋地域で、バイオ製薬・ヘルスケア業界に統合ソリューションを提供するための製品・プロセスの設計、製造、販売に従事している。バイオ医薬品・診断ソリューション部門とエンジニアリング部門の2部門で事業を展開。主な製品は、封じ込めソリューション、ドラッグデリバリーシステム、医療機器、診断、分析サービス、外観検査機、組立包装機、ガラス成形機など。同社は1949年に設立され、イタリアのピオンビーノ・デセに本社を置く。Stevanato Group S.p.A.はStevanato Holding S.R.L.の子会社である。もっと見るStevanato Group S.p.A. 基礎のまとめStevanato Group の収益と売上を時価総額と比較するとどうか。STVN N 基礎統計学時価総額Mex$85.27b収益（TTM）Mex$2.82b売上高(TTM)Mex$23.99b30.3xPER（株価収益率3.6xP/SレシオSTVN N は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計STVN N 損益計算書（TTM）収益€1.20b売上原価€851.68m売上総利益€351.58mその他の費用€210.23m収益€141.35m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.52グロス・マージン29.22%純利益率11.75%有利子負債／自己資本比率28.3%STVN N の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.3%現在の配当利回り10%配当性向STVN N 配当は確実ですか？STVN N 配当履歴とベンチマークを見るSTVN N 、いつまでに購入すれば配当金を受け取れますか？Stevanato Group 配当日配当落ち日Jun 11 2026配当支払日Jul 29 2026配当落ちまでの日数51 days配当支払日までの日数3 daysSTVN N 配当は確実ですか？STVN N 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/28 10:31終値2026/03/31 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Stevanato Group S.p.A. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Curtis MoilesBNP ParibasHugo SolvetBNP ParibasMichael RyskinBofA Global Research17 その他のアナリストを表示
お知らせ • Jul 31Stevanato Group Announces Marketing Authorizations for Liraglutide-Based Combination Products Incorporating Alina Pen Injector in Multiple European CountriesStevanato Group S.p. A announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders. The approved configurations include Alina 30, developed for liraglutide-based therapies for diabetes, and Alina 50, designed for liraglutide-based weight management applications. Both variants are part of Stevanato Group's broader Alina variable-dose pen injector platform, which offers multiple pre-configured variants for GLP-1s and other injectable therapies. Alina features a dial-a-dose mechanism with visual, audible, and tactile feedback during dose selection and injection, and compatibility with ISO standard 3 mL glass cartridges. The platform has been designed to support manufacturing scalability, and integration into existing pharmaceutical fill and finish and final assembly supply chains. These authorizations come at a time when injectable therapies are playing an increasingly important role in healthcare, driven by the ongoing expansion of GLP-1 treatments and the broader shift towards patient-centric models of care and self-administration. Through its proprietary device portfolio – including Alina (variable-dose, pen injector), Deora (fixed-dose, pen injector), Aidaptus (autoinjector) and Vertiva (on-body delivery system) – Stevanato Group is expanding its drug delivery capabilities to support pharmaceutical and biotechnology companies developing next-generation therapies. Alina is manufactured within Stevanato Group's Drug Delivery Systems operations and leverages the Company's integrated expertise across pharmaceutical glass containers, engineering technologies, analytical services and device manufacturing. The platform has been designed to offer pharmaceutical partners a flexible and production-ready solution capable of supporting commercial-scale deployment. Alina is a variable-dose, disposable pen injector platform designed for subcutaneous drug delivery. The platform can accommodate doses from 0.01 mL up to 0.75 mL and includes multiple pre-configured variants developed for GLP-1 and other injectable therapies. Alina combines familiar handling, enhanced dose readability and flexible customization options to support a wide range of therapeutic requirements.
お知らせ • Jul 21Stevanato Group S.p.A. to Report Q2, 2026 Results on Aug 04, 2026Stevanato Group S.p.A. announced that they will report Q2, 2026 results at 6:30 AM, US Eastern Standard Time on Aug 04, 2026
お知らせ • Jun 10Stevanato Group Introduces Deora Pen Injector Platform for Subcutaneous Delivery in Diabetes and Weight ManagementStevanato Group S.p.A. introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is Stevanato Group’s multi-use, fixed-dose pen injector designed for subcutaneous drug delivery in therapies such as diabetes and weight management. Featuring an intuitive pull-push mechanism, the device simplifies dose administration by eliminating the need for manual dose selection: users pull to set the dose and push to inject, supporting consistent delivery across multiple administrations. The platform accommodates fixed-dose volumes up to 0.75 mL and is compatible with standard 1.5 mL and 3 mL cartridges, offering flexibility across a range of therapeutic applications. Engineered with patient usability in mind, Deora™ provides tactile, visual, and audible feedback during operation, helping reduce common sources of use error. Its architecture is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing for pharmaceutical partners. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL. The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing. Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format. Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs. Deora™ leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialization. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners. Together, these characteristics position Deora™ as a platform intended to support partners as they advance early development programs and prepare for future scale-up.
お知らせ • Jun 04Stevanato Group S.p.A. Approves Dividend on Class A ShareStevanato Group S.p.A. at its Ordinary and Extraordinary Meeting of Shareholders held on May 26, 2026 approved distribution of dividends in the amount of EUR 0.054 for each outstanding Class A and ordinary share of the Company, net of the treasury shares.
お知らせ • May 30Stevanato Group S.p.A. Appoints Peter Soelkner as Non-Executive Director, Effective 26 May 2026Oxford Biomedica plc announced that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independent Non-Executive Director has been appointed as a Non-Executive Director of Stevanato Group S.p.A, a NASDAQ listed company with effect from 26 May 2026.
お知らせ • May 12Stevanato Group S.p.A., Annual General Meeting, May 26, 2026Stevanato Group S.p.A., Annual General Meeting, May 26, 2026.
お知らせ • Jul 31Stevanato Group Announces Marketing Authorizations for Liraglutide-Based Combination Products Incorporating Alina Pen Injector in Multiple European CountriesStevanato Group S.p. A announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders. The approved configurations include Alina 30, developed for liraglutide-based therapies for diabetes, and Alina 50, designed for liraglutide-based weight management applications. Both variants are part of Stevanato Group's broader Alina variable-dose pen injector platform, which offers multiple pre-configured variants for GLP-1s and other injectable therapies. Alina features a dial-a-dose mechanism with visual, audible, and tactile feedback during dose selection and injection, and compatibility with ISO standard 3 mL glass cartridges. The platform has been designed to support manufacturing scalability, and integration into existing pharmaceutical fill and finish and final assembly supply chains. These authorizations come at a time when injectable therapies are playing an increasingly important role in healthcare, driven by the ongoing expansion of GLP-1 treatments and the broader shift towards patient-centric models of care and self-administration. Through its proprietary device portfolio – including Alina (variable-dose, pen injector), Deora (fixed-dose, pen injector), Aidaptus (autoinjector) and Vertiva (on-body delivery system) – Stevanato Group is expanding its drug delivery capabilities to support pharmaceutical and biotechnology companies developing next-generation therapies. Alina is manufactured within Stevanato Group's Drug Delivery Systems operations and leverages the Company's integrated expertise across pharmaceutical glass containers, engineering technologies, analytical services and device manufacturing. The platform has been designed to offer pharmaceutical partners a flexible and production-ready solution capable of supporting commercial-scale deployment. Alina is a variable-dose, disposable pen injector platform designed for subcutaneous drug delivery. The platform can accommodate doses from 0.01 mL up to 0.75 mL and includes multiple pre-configured variants developed for GLP-1 and other injectable therapies. Alina combines familiar handling, enhanced dose readability and flexible customization options to support a wide range of therapeutic requirements.
お知らせ • Jul 21Stevanato Group S.p.A. to Report Q2, 2026 Results on Aug 04, 2026Stevanato Group S.p.A. announced that they will report Q2, 2026 results at 6:30 AM, US Eastern Standard Time on Aug 04, 2026
お知らせ • Jun 10Stevanato Group Introduces Deora Pen Injector Platform for Subcutaneous Delivery in Diabetes and Weight ManagementStevanato Group S.p.A. introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is Stevanato Group’s multi-use, fixed-dose pen injector designed for subcutaneous drug delivery in therapies such as diabetes and weight management. Featuring an intuitive pull-push mechanism, the device simplifies dose administration by eliminating the need for manual dose selection: users pull to set the dose and push to inject, supporting consistent delivery across multiple administrations. The platform accommodates fixed-dose volumes up to 0.75 mL and is compatible with standard 1.5 mL and 3 mL cartridges, offering flexibility across a range of therapeutic applications. Engineered with patient usability in mind, Deora™ provides tactile, visual, and audible feedback during operation, helping reduce common sources of use error. Its architecture is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing for pharmaceutical partners. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL. The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing. Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format. Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs. Deora™ leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialization. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners. Together, these characteristics position Deora™ as a platform intended to support partners as they advance early development programs and prepare for future scale-up.
お知らせ • Jun 04Stevanato Group S.p.A. Approves Dividend on Class A ShareStevanato Group S.p.A. at its Ordinary and Extraordinary Meeting of Shareholders held on May 26, 2026 approved distribution of dividends in the amount of EUR 0.054 for each outstanding Class A and ordinary share of the Company, net of the treasury shares.
お知らせ • May 30Stevanato Group S.p.A. Appoints Peter Soelkner as Non-Executive Director, Effective 26 May 2026Oxford Biomedica plc announced that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independent Non-Executive Director has been appointed as a Non-Executive Director of Stevanato Group S.p.A, a NASDAQ listed company with effect from 26 May 2026.
お知らせ • May 12Stevanato Group S.p.A., Annual General Meeting, May 26, 2026Stevanato Group S.p.A., Annual General Meeting, May 26, 2026.
お知らせ • May 09Stevanato Group S.p.A. Maintains Earnings Guidance for the Fiscal Year 2026Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be in the range of EUR 1,260.0 million to EAR 1,290.0 million. Operating profit to be EUR 212.7 million to EUR 227.8 million. Net profit to be EUR 149.6 million to EUR 160.7 million. Diluted EPS to be EUR 0.55 to EUR 0.59.
お知らせ • Apr 24Stevanato Group S.p.A. to Report Q1, 2026 Results on May 07, 2026Stevanato Group S.p.A. announced that they will report Q1, 2026 results at 6:30 AM, Eastern Daylight on May 07, 2026
お知らせ • Mar 05Stevanato Group S.P.A. Provides Earnings Guidance for the Fiscal 2026Stevanato Group S.p.A. provided earnings guidance for the fiscal 2026. For the year, the company expected revenue in the range of €1.26 billion to €1.29 billion; Operating Profit of €212.7 million to €227.8 million; Net Profit of €149.6 million to €160.7 million; Diluted EPS of €0.55 to €0.59.
お知らせ • Feb 19Stevanato Group S.p.A. to Report Q4, 2025 Results on Mar 04, 2026Stevanato Group S.p.A. announced that they will report Q4, 2025 results at 6:30 AM, US Eastern Standard Time on Mar 04, 2026
お知らせ • Nov 07Stevanato Group S.P.A. Maintains Revenue Guidance for the 2025Stevanato Group S.p.A. maintained revenue guidance for the 2025. For the period, the company expects Revenue in the range of €1.160 billion to €1.190 billion.
お知らせ • Oct 22Stevanato Group S.p.A. to Report Q3, 2025 Results on Nov 06, 2025Stevanato Group S.p.A. announced that they will report Q3, 2025 results at 6:30 AM, Eastern Standard Time on Nov 06, 2025
お知らせ • Aug 05Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the period, the company continues to expect revenue in the range of €1.160 billion to €1.190 billion.
お知らせ • Jul 23Stevanato Group S.p.A. to Report Q2, 2025 Results on Aug 05, 2025Stevanato Group S.p.A. announced that they will report Q2, 2025 results at 6:30 AM, US Eastern Standard Time on Aug 05, 2025
お知らせ • Jun 10+ 1 more updateStevanato Group S.p.A. Approves Board AppointmentsStevanato Group S.p.A. at its Ordinary Meeting of Shareholders held on May 23, 2025 approved appointment of Sue Jean Lin and Elisabetta Magistretti to its board of directors.
お知らせ • May 08Stevanato Group S.P.A. Maintains Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. maintained earnings guidance for the fiscal year 2025. For the year, the company expects revenue in the range of €1.160 billion to €1.190 billion.
お知らせ • May 05Stevanato Group S.p.A., Annual General Meeting, May 23, 2025Stevanato Group S.p.A., Annual General Meeting, May 23, 2025, at 16:00 W. Europe Standard Time.
お知らせ • Apr 25Stevanato Group S.p.A. to Report Q1, 2025 Results on May 08, 2025Stevanato Group S.p.A. announced that they will report Q1, 2025 results at 6:30 AM, Eastern Standard Time on May 08, 2025
お知らせ • Mar 06Stevanato Group S.p.A. Provides Earnings Guidance for the Fiscal Year 2025Stevanato Group S.p.A. provided earnings guidance for the fiscal year 2025. For the year, the Company expected revenue in the range of €1,160 million to €1,190 million.
お知らせ • Feb 25Stevanato Group S.p.A. to Report Q4, 2024 Results on Mar 06, 2025Stevanato Group S.p.A. announced that they will report Q4, 2024 results at 6:30 AM, US Eastern Standard Time on Mar 06, 2025
お知らせ • Nov 05Stevanato Group S.P.A. Provides Earnings Guidance for the Full Year 2024Stevanato Group S.p.A. provided earnings guidance for the full year 2024. for the year, the company expects reported revenue of €1,090.0 million to €1,110.0 million, reported Operating Profit of €155.8 million to €161.8 million, reported Net Profit of €115.0 million to €119.4 million, reported Diluted EPS €0.42-€0.44.
お知らせ • Oct 23Stevanato Group S.p.A. to Report Q3, 2024 Results on Nov 05, 2024Stevanato Group S.p.A. announced that they will report Q3, 2024 results at 6:30 AM, US Eastern Standard Time on Nov 05, 2024
お知らせ • Oct 01Stevanato Group S.p.A. to Introduce Its Large-Volume Vertiva 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI MilanStevanato Group S.p. A. announced the expansion of its Vertiva platform, which will include a 10mL option to be presented at CPHI Milan in October. The Vertiva®? easy-to-use platform can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-content bolus injections. This flexibility makes the platform ideal for administering a wide range of small molecule and biologic therapies, enabling treatment for conditions such as cardiovascular and metabolic disorders, oncology, immunology, and pain management. The Vertiva®? platform features a unique design with a single-use pod containing a pre-filled, pre-loaded cartridge, paired with a reusable, smart controller that communicates with a patented and magnetically coupled drive mechanism. The pod, securely interlocked with the controller, contains a pre-filled glass cartridge available in formats ranging from 3mL up to 10mL and is assembled at the factory for immediate use. This simplifies home-based treatment initiation, offering patients a safe and comfortable experience. A recent wearability study underscored this sentiment and revealed that Vertiva®? 10mL is generally well-accepted by patients who found it comfortable to wear. The device proved to securely adhere to the body without restricting movement, allowing patients to go about their daily activities easily. The smart controller provides the option to record patient usage data, which can be transferred via Bluetooth to digital health applications. Additionally, the two-part system allows for easy separation of the reusable controller from the disposable pod after treatment, significantly reducing the environmental impact of electronic components and enhancing the device's overall sustainability. Stevanato Group will leverage its integrated capabilities and its existing partnership with Thermo Fisher Scientific to bring Vertiva®? 10mL to market. Along with the proprietary device platform, Stevanato Group will offer its pre-sterilized EZ-fill®? cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services. The unparalleled combination of capabilities from two established industry providers will support pharma companies from drug development through to the final packaged product, reducing risks and accelerating time-to-market. Demonstrations of Vertiva®? 10mL will be available at CPHI in Milan (Oct 8-10) at Stevanato Group's booth, 20C1.
お知らせ • Aug 06Stevanato Group S.p.A. Updates Earnings Guidance for the Year 2024Stevanato Group S.p.A. updated earnings guidance for the year 2024. For the year, the company expects reported revenue to be between €1,090 million to €1,110 million. Reported operating profit to be between €162.9 million to €170.9 million. Reported net profit to be between €119.5 million to €125.5 million. Reported diluted EPS to be between €0.44 to €0.46.
お知らせ • Jul 25Stevanato Group S.p.A. to Report Q2, 2024 Results on Aug 06, 2024Stevanato Group S.p.A. announced that they will report Q2, 2024 results at 6:30 AM, US Eastern Standard Time on Aug 06, 2024
お知らせ • May 29Stevanato Group S.P.A. Announces Chief Executive Officer ChangesStevanato Group S.P.A. announced that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024. Mr. Moro will remain on the Company’s Board of Directors. Mr. Stevanato has held the position of Executive Chairman since 2021 and he previously served as Chief Executive Officer of Stevanato Group from 1998 to 2021. He is the driving force behind the Group’s long-term strategic vision and integrated value proposition. Mr. Stevanato is responsible for leading the Company’s global expansion over the last two decades, expanding the Company’s diversified product portfolio, establishing the Group’s science-based technology excellence centers, enhancing its research and development capabilities, and leading the Company through its initial public offering.
お知らせ • May 10Stevanato Group S.P.A. Provides Revenue Guidance for 2024Stevanato Group S.p.A. provided revenue guidance for 2024. For the period, the company expects revenue in the range of €1,125 million to €1,155 million.
お知らせ • Apr 28Stevanato Group S.p.A. to Report Q1, 2024 Results on May 09, 2024Stevanato Group S.p.A. announced that they will report Q1, 2024 results at 6:30 AM, US Eastern Standard Time on May 09, 2024
お知らせ • Apr 05Stevanato Group S.p.A. Announces the Appointment of Ugo Gay as Chief Operations OfficerStevanato Group S.p.A. announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). The addition of Ugo Gay underscores Stevanato Group’s unwavering commitment to driving operational efficiency, process standardization, and sustainable growth across its global value chain. Ugo Gay brings to Stevanato Group nearly three decades of experience in industry, business management, supply chain, and operations. Prior to joining Stevanato Group, Ugo held key leadership positions at renowned organizations, including the Biological Chemotherapy Institute of Turin and Diasorin, an Italian multinational biotechnology company. At Diasorin, Ugo served in various roles, from Sales to Industrial Operations, culminating in his tenure as CEO and General Manager of the new subsidiary Diasorin Italia S.p.A. In his new role as COO of Stevanato Group, Ugo Gay will shape and execute sourcing, planning, and manufacturing strategies to help drive the Company's growth and achieve its business goals and vision. With a keen focus on maximizing returns on investments and driving efficiencies, Ugo will oversee priority strategic projects and lead the development and management of information systems to support the Company's development and standardization of processes. Ugo Gay officially assumed his role as Chief Operations Officer on March 25, 2024, and will be based at Piombino Dese.
お知らせ • Mar 22Stevanato Group S.p.A. has filed a Follow-on Equity Offering in the amount of $300 million.Stevanato Group S.p.A. has filed a Follow-on Equity Offering in the amount of $300 million. Security Name: Common Stock Security Type: Common Stock
お知らせ • Mar 07Stevanato Group S.P.A. Provides Revenue Guidance for the Full Year of 2024Stevanato Group S.p.A. provided revenue guidance for the full year of 2024. For the year, company expects Revenue in the range of €1,180 million to €1,210 million.
お知らせ • Feb 23Stevanato Group S.p.A. to Report Q4, 2023 Results on Mar 07, 2024Stevanato Group S.p.A. announced that they will report Q4, 2023 results at 6:30 AM, Eastern Standard Time on Mar 07, 2024
お知らせ • Jan 24Stevanato Group S.p.A. Launches EZ-fill®? Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and CommercializationStevanato Group S.p. A. unveiled two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers (TEC). In a context where reducing time-to-market is key, Stevanato Group's new EZ-fill®? Kit offers fast access to a customizable and versatile solution to pharma and biotech companies needing to efficiently fill small batches with high-quality injectable formulations during clinical trials or commercial phases. The surge the industry has seen in biopharmaceuticals treating various diseases in several therapeutical areas may signal a significant growth potential for pharmaceutical companies. Injectables, comprising more than 60% of the over 21,000 drugs currently in development, of which 44% are biopharmaceuticals, require high-performance primary packaging and delivery technologies for proper storage and administration. The company’s EZ-fill® Kit builds on its existing ready-to-use platform of pre-sterilized containment solutions – vials, cartridges, and syringes – allowing customers to effectively screen different primary packaging in combination with drug products. The kit will be available as a modular box made up of glass ready-to-use drug containers and add-on components on request, shipped by courier. As a result, the platform can bring enhanced levels of quality and safety to patients across the entire drug life cycle and improve the rate at which new drugs enter the market. EZ-fill® Kit will be presented at Pharmapack and is expected to be available commercially beginning in the second quarter of 2024.
お知らせ • Nov 01Stevanato Group S.P.A. Reiterates Revenue Guidance for the Full Year 2023Stevanato Group S.p.A. reiterated revenue guidance for the full year 2023. For the year, company expects Revenue in the range of €1.085 billion to €1.115 billion.
お知らせ • Oct 18Stevanato Group S.p.A. to Report Q3, 2023 Results on Oct 31, 2023Stevanato Group S.p.A. announced that they will report Q3, 2023 results at 6:30 AM, US Eastern Standard Time on Oct 31, 2023
Reported Earnings • Aug 08Second quarter 2023 earnings released: EPS: €0.13 (vs €0.12 in 2Q 2022)Second quarter 2023 results: EPS: €0.13 (up from €0.12 in 2Q 2022). Revenue: €255.3m (up 9.0% from 2Q 2022). Net income: €34.2m (up 12% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Global Life Sciences industry.
お知らせ • Jul 29Stevanato Group S.P.A. Provides Revenue Guidance for the Year 2023Stevanato Group S.p.A. provided revenue guidance for the year 2023. For the period, the company expects revenue in the range of €1.085 billion to €1.115 billion.
お知らせ • Jul 15Stevanato Group S.p.A. to Report Q2, 2023 Results on Jul 28, 2023Stevanato Group S.p.A. announced that they will report Q2, 2023 results at 6:30 AM, US Eastern Standard Time on Jul 28, 2023
お知らせ • Jun 13Stevanato Group S.p.A. Unveils Vertiva On-Body Delivery System Platform for Wide Range of Injectable Therapies and for Large Delivery Volumes (Up to 10mL)Stevanato Group S.p.A. unveiled Vertiva, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies. Vertiva's unique design consists of a single-use pod with a pre-filled and pre-loaded 3mL ISO cartridge, and a multi-use controller, offering potential sustainability and affordability benefits. These two parts communicate through a patented magnetically coupled drive mechanism. The device can adapt to different delivery profiles and can enable the administration of small-molecule drugs and biologics. Vertiva's design is under development also to cover a broad range of volumes up to 10mL. In the Vertiva device the cartridge is preloaded and sealed into the pod during factory assembly allowing the patient to benefit from simplified treatment initiation. Administrations can be conducted more comfortably at home, and the connectivity options of Vertiva can be ready for digital health applications. Upon treatment, the pod and controller can be more easily separated, and the controller can be reused, thereby reducing the environmental impact of electronic components. Fully programmable to deliver micro-precision basal doses and full-content bolus injections, Vertiva is intended to be suitable for awide range of therapies, such as cardiovascular and metabolic disorders, oncology, immunology, and pain diseases. Vertiva platform can also accommodate different customizations, including primary packaging format for larger injection volumes, delivery duration, and user interface. The Vertiva brand name takes its cue from the word 'versatility' and suggests that the delivery profile is flexible, as it is programmable for basal and bolus delivery. The name also evokes ease of use for patients. Stevanato Group will leverage the recently announced collaboration with Thermo Fisher Scientific to bring Vertiva to market. The platform will be offered as an integrated device and fill-and-finish solution to streamline the management of the pharmaceutical supply chain. The unparalleled combination of capabilities from two established industry providers can support pharma companies from drug development through to the final packaged product. Along with the proprietary device platform, Stevanato Group will offer its pre-sterilized EZ-fill cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services.
お知らせ • Jun 08Stevanato Group S.p.A. Announces Dividend, Payable on July 17, 2023Stevanato Group S.p.A. announced that it has changed the previously announced ex-dividend date of June 5, 2023 for its cash dividend of EUR 0.054 per share, payable on July 17, 2023, to comply with New York Stock Exchange rules. The new ex-dividend date for the dividend will be June 7, 2023, and the record date remains June 6, 2023. The dividend will continue to be payable on July 17, 2023.
お知らせ • May 05Stevanato Group S.p.A. Reiterates Earnings Guidance for the Year 2023Stevanato Group S.p.A. reiterated earnings guidance for the year 2023. The Company is reiterating its fiscal year 2023 guidance and still expects: Revenue in the range of €1.085 billion to €1.115 billion, Operating Profit in the range of €199.9 million to €211.9 million, net profit in the range of €147.8 million to €156.9 million and Diluted EPS in the range of €0.56 to €0.59.
Reported Earnings • Mar 04Full year 2022 earnings released: EPS: €0.54 (vs €0.53 in FY 2021)Full year 2022 results: EPS: €0.54 (up from €0.53 in FY 2021). Revenue: €983.7m (up 17% from FY 2021). Net income: €143.0m (up 6.5% from FY 2021). Profit margin: 14% (down from 16% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Global Life Sciences industry.
お知らせ • Feb 17Stevanato Group S.p.A. to Report Q4, 2022 Results on Mar 02, 2023Stevanato Group S.p.A. announced that they will report Q4, 2022 results at 6:30 AM, US Eastern Standard Time on Mar 02, 2023
Valuation Update With 7 Day Price Move • Dec 09Investor sentiment improved over the past weekAfter last week's 15% share price gain to Mex$332, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 31x in the Life Sciences industry globally. Simply Wall St's valuation model estimates the intrinsic value at Mex$221 per share.
